Serum S100B and BDNF levels in women with fibromyalgia
The Relationship Between Serum S100B and Brain-Derived Neurotrophic Factor (BDNF) Levels and Central Sensitization and Sleep Quality in Patients With Fibromyalgia
This project tests whether blood levels of S100B and BDNF differ in women 18–50 with fibromyalgia compared with healthy women and whether those levels relate to central sensitization and sleep quality.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | Female |
| Sponsor | Kanuni Sultan Suleyman Training and Research Hospital Academic / other |
| Locations | 1 site (Istanbul) |
| Trial ID | NCT07358754 on ClinicalTrials.gov |
What this trial studies
This cross-sectional observational study compares serum S100B and BDNF in women diagnosed with fibromyalgia (2016 ACR criteria) and age- and sex-matched healthy controls. Participants will complete questionnaires on symptoms, central sensitization, and sleep, and provide a single blood sample for biomarker measurement. Analyses will compare biomarker levels between groups and test associations between those levels and measures of central sensitization and sleep quality. The study is designed to clarify biomarker patterns rather than to alter clinical care.
Who should consider this trial
Good fit: Women aged 18–50 with a diagnosis of fibromyalgia per 2016 ACR criteria, symptoms for at least three months, who can complete questionnaires and provide informed consent.
Not a fit: Men, people outside the 18–50 age range, individuals without fibromyalgia, or patients seeking immediate therapy changes are unlikely to receive direct benefit from this observational biomarker study.
Why it matters
Potential benefit: If successful, the findings could identify blood markers that help explain fibromyalgia symptoms and inform future diagnostic or treatment research.
How similar studies have performed: Previous studies have reported altered BDNF and S100B in chronic pain and fibromyalgia, but results have been inconsistent and not yet definitive.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female participants aged between 18 and 50 years Diagnosis of fibromyalgia according to 2016 American College of Rheumatology (ACR) criteria Symptoms present for at least 3 months Ability to understand and complete study questionnaires Provision of written informed consent For healthy controls: No diagnosis of fibromyalgia or chronic widespread pain No known systemic disease Exclusion Criteria: \-
Where this trial is running
Istanbul
- Kanuni Sultan Süleyman Training and Research Hospital — Istanbul, Turkey (Türkiye) (Recruiting)
Study contacts
- Principal investigator: Zeynep Karakuzu Güngör, M.D — Kanuni Sultan Süleyman Training and Research Hospital
- Study coordinator: Zeynep Karakuzu Güngör, M.D
- Email: zeynepkarakuzu@hotmail.com.tr
- Phone: 905077750375
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.